JAGUAR HEALTH, INC. Net Income (Loss) Available to Common Stockholders, Basic
JAGUAR HEALTH, INC. (JAGX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$12.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-19
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$12.70M.
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$7.01M.
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$23.20M.
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$9.50M.
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$53.58M.
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$38.49M.
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$41.30M.
- JAGUAR HEALTH, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$47.45M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.70M 10-Q · filed 2026-08-19 | -$19.72M 10-Q · filed 2026-08-19 | -$42.92M derived: sum of 3 quarters · filed 2026-08-19 | -$52.42M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$7.01M 10-Q · filed 2026-05-20 | -$30.22M derived: sum of 2 quarters · filed 2026-05-20 | -$39.72M derived: sum of 3 quarters · filed 2026-05-20 | -$50.13M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | -$23.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$32.70M derived: sum of 2 quarters · filed 2026-04-07 | -$43.11M derived: sum of 3 quarters · filed 2026-08-19 | -$53.58M 10-K · filed 2026-04-07 |
| 2025-09-30 | -$9.50M 10-Q · filed 2025-11-14 | -$19.91M derived: sum of 2 quarters · filed 2026-08-19 | -$30.37M 10-Q · filed 2025-11-14 | -$40.29M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$10.41M 10-Q · filed 2026-08-19 | -$20.87M 10-Q · filed 2026-08-19 | -$30.79M derived: sum of 3 quarters · filed 2026-08-19 | -$40.65M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$10.46M 10-Q · filed 2026-05-20 | -$20.38M derived: sum of 2 quarters · filed 2026-05-20 | -$30.24M derived: sum of 3 quarters · filed 2026-05-20 | -$39.73M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$19.77M derived: sum of 2 quarters · filed 2026-04-07 | -$29.27M derived: sum of 3 quarters · filed 2026-04-07 | -$38.49M 10-K · filed 2026-04-07 |
| 2024-09-30 | -$9.85M 10-Q · filed 2025-11-14 | -$19.35M derived: sum of 2 quarters · filed 2025-11-14 | -$28.57M 10-Q · filed 2025-11-14 | -$37.74M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$9.49M 10-Q · filed 2025-08-14 | -$18.72M 10-Q · filed 2025-08-14 | -$27.89M derived: sum of 3 quarters · filed 2025-08-14 | -$35.67M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$9.23M 10-Q · filed 2025-05-15 | -$18.40M derived: sum of 2 quarters · filed 2025-05-15 | -$26.17M derived: sum of 3 quarters · filed 2025-05-15 | -$38.32M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$9.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$16.95M derived: sum of 2 quarters · filed 2025-03-31 | -$29.10M derived: sum of 3 quarters · filed 2025-03-31 | -$41.30M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$7.78M 10-Q · filed 2024-11-13 | -$19.93M derived: sum of 2 quarters · filed 2024-11-13 | -$32.13M 10-Q · filed 2024-11-13 | -$39.71M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$12.15M 10-Q · filed 2024-08-13 | -$24.35M 10-Q · filed 2024-08-13 | -$31.93M derived: sum of 3 quarters · filed 2024-08-13 | -$44.45M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$12.20M 10-Q · filed 2024-05-14 | -$19.78M derived: sum of 2 quarters · filed 2024-05-14 | -$32.30M derived: sum of 3 quarters · filed 2024-05-14 | -$41.67M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$20.10M derived: sum of 2 quarters · filed 2024-04-01 | -$29.47M derived: sum of 3 quarters · filed 2024-04-01 | -$47.45M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$12.52M 10-Q · filed 2023-11-14 | -$21.89M derived: sum of 2 quarters · filed 2023-11-14 | -$39.87M 10-Q · filed 2023-11-14 | -$54.19M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$9.37M 10-Q · filed 2023-08-14 | -$27.35M 10-Q · filed 2023-08-14 | -$41.67M derived: sum of 3 quarters · filed 2023-08-14 | -$53.86M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$17.99M 10-Q · filed 2023-05-15 | -$32.30M derived: sum of 2 quarters · filed 2023-05-15 | -$44.49M derived: sum of 3 quarters · filed 2023-05-15 | -$58.57M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$14.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$26.50M derived: sum of 2 quarters · filed 2023-03-24 | -$40.59M derived: sum of 3 quarters · filed 2023-03-24 | -$52.59M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$12.19M 10-Q · filed 2022-11-14 | -$26.27M derived: sum of 2 quarters · filed 2022-11-14 | -$38.28M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$14.08M 10-Q · filed 2022-08-22 | -$26.09M 10-Q · filed 2022-08-22 | ||
| 2021-03-31 | -$12.01M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$38.65M 10-K · filed 2022-03-11 | |||
| 2018-12-31 | -$11.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | -$17.80M derived: sum of 2 quarters · filed 2019-04-10 | -$26.45M derived: sum of 3 quarters · filed 2019-04-10 | -$32.15M 10-K · filed 2019-04-10 |
| 2018-09-30 | -$6.14M 10-Q · filed 2018-11-19 | -$14.79M derived: sum of 2 quarters · filed 2018-11-19 | -$20.49M 10-Q · filed 2018-11-19 | -$41.69M derived: sum of 4 quarters · filed 2019-04-10 |
| 2018-06-30 | -$8.65M 10-Q · filed 2018-08-13 | -$14.35M 10-Q · filed 2018-08-13 | -$35.55M derived: sum of 3 quarters · filed 2019-04-10 | -$30.79M derived: sum of 4 quarters · filed 2019-04-10 |
| 2018-03-31 | -$6.69M 10-Q · filed 2018-05-15 | -$26.90M derived: sum of 2 quarters · filed 2019-04-10 | -$22.14M derived: sum of 3 quarters · filed 2019-04-10 | -$23.94M derived: sum of 4 quarters · filed 2019-04-10 |
| 2017-12-31 | -$20.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | -$15.45M derived: sum of 2 quarters · filed 2019-04-10 | -$17.25M derived: sum of 3 quarters · filed 2019-04-10 | -$21.97M 10-K · filed 2019-04-10 |
| 2017-09-30 | $4.76M 10-Q · filed 2018-11-19 | $2.95M derived: sum of 2 quarters · filed 2018-11-19 | -$1.76M 10-Q · filed 2018-11-19 | -$5.44M derived: sum of 4 quarters · filed 2018-11-19 |
| 2017-06-30 | -$1.81M 10-Q · filed 2018-08-13 | -$6.52M 10-Q · filed 2018-08-13 | -$10.20M derived: sum of 3 quarters · filed 2018-08-13 | -$13.61M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | -$4.72M 10-Q · filed 2018-05-15 | -$8.39M derived: sum of 2 quarters · filed 2018-05-15 | -$11.81M derived: sum of 3 quarters · filed 2018-05-15 | -$15.46M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | -$3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | -$7.09M derived: sum of 2 quarters · filed 2018-04-09 | -$10.75M derived: sum of 3 quarters · filed 2018-04-09 | -$14.73M 10-K · filed 2018-04-09 |
| 2016-09-30 | -$3.42M 10-Q · filed 2017-11-20 | -$7.07M derived: sum of 2 quarters · filed 2017-11-20 | -$11.06M 10-Q · filed 2017-11-20 | -$15.19M derived: sum of 4 quarters · filed 2017-11-20 |
| 2016-06-30 | -$3.66M 10-Q · filed 2017-08-09 | -$7.64M 10-Q · filed 2017-08-09 | -$11.77M derived: sum of 3 quarters · filed 2017-08-09 | -$14.73M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | -$3.98M 10-Q/A · filed 2017-06-23 | -$8.12M derived: sum of 2 quarters · filed 2017-06-23 | -$11.08M derived: sum of 3 quarters · filed 2017-06-23 | -$16.50M derived: sum of 4 quarters · filed 2017-06-23 |
| 2015-12-31 | -$4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | -$7.09M derived: sum of 2 quarters · filed 2017-02-15 | -$12.51M derived: sum of 3 quarters · filed 2017-02-15 | -$16.64M 10-K · filed 2017-02-15 |
| 2015-09-30 | -$2.96M 10-Q · filed 2016-11-14 | -$8.38M derived: sum of 2 quarters · filed 2016-11-14 | -$12.51M 10-Q · filed 2016-11-14 | -$14.66M derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | -$5.42M 10-Q · filed 2016-08-15 | -$9.55M 10-Q · filed 2016-08-15 | -$11.70M derived: sum of 3 quarters · filed 2016-08-15 | -$14.61M derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | -$4.12M 10-Q · filed 2016-05-10 | -$6.27M derived: sum of 2 quarters · filed 2016-05-10 | -$9.19M derived: sum of 3 quarters · filed 2016-05-10 | -$11.33M derived: sum of 4 quarters · filed 2016-05-10 |
| 2014-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | -$5.06M derived: sum of 2 quarters · filed 2016-03-29 | -$7.21M derived: sum of 3 quarters · filed 2016-03-29 | -$9.26M 10-K · filed 2016-03-29 |
| 2014-09-30 | -$2.91M 10-Q · filed 2015-11-13 | -$5.06M derived: sum of 2 quarters · filed 2015-11-13 | -$7.11M 10-Q · filed 2015-11-13 | |
| 2014-06-30 | -$2.15M 10-Q · filed 2015-08-13 | -$4.20M 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | -$2.05M 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |